Abstract
This study became the foundation of the development program culminating in the approval of apomorphine SL for the treatment of erectile dysfunction (ED). Using this formulation, the Canadian group showed that the benefit of apomorphine, i.e., a good erectile response, can be achieved in the absence of compliance- limiting side effects.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
13.1 Key Trial References
13.1.1 Major Publication
Heaton J, Morales A, et al. Recovery of erectile function by the oral administration of apomorphine. Urology 45(2):200–206, 1995.
13.1.2 Other Important Publications
Dula E, Bukofzer S, et al. Double-blind, crossover comparison of 3mg apomorphine SL with placebo and 4 mg apomorphine in male erectile dysfunction. Eur Urol 39:558–564, 2001.
Heaton J. Key issues from the clinical trials of apomorphine SL. World J Urol 19(1):25–31, 2001.
Heaton J, Altwein J. The role of apomorphine SL in the treatment of male erectile dysfunction. BJU Int 88(Suppl 3):36–38, 2001.
Rights and permissions
Copyright information
© 2007 Springer-Verlag London Limited
About this chapter
Cite this chapter
(2007). Pilot Study Showing Benefit of Clinical Response to Apomorphine Sublingual (SL). In: Key Clinical Trials in Erectile Dysfunction. Springer, London. https://doi.org/10.1007/978-1-84628-428-1_13
Download citation
DOI: https://doi.org/10.1007/978-1-84628-428-1_13
Publisher Name: Springer, London
Print ISBN: 978-1-84628-427-4
Online ISBN: 978-1-84628-428-1
eBook Packages: MedicineMedicine (R0)